CARSGEN-B (02171) experienced a surge of over 9% in early trading, reaching a gain of 9.49% to HKD 17.66, with a trading volume of HKD 11.95 million. The company announced that the research results for Zewokilanse injection (Product ID: CT053), an autologous CAR-T cell product targeting BCMA, were presented in a poster session at the 2025 European Society for Medical Oncology (ESMO) annual meeting. This clinical trial represents the world's first proof-of-concept study investigating CAR-T cell therapy for adjuvant treatment in solid tumors, specifically for pancreatic cancer (PC). Notably, on September 20, the National Healthcare Security Administration announced the completion of expert review work for the first version of the innovative drug directory for commercial insurance. It is reported that all five CAR-T drugs, including CARSGEN-B's Zewokilanse, passed expert review and are expected to be included in this year's basic medical insurance directory and the commercial insurance innovative drug directory.